Search Results for keywords:"research and development"

LTS Therapy Systems, LLC is seeking to become a registered importer of certain controlled substances for research and development purposes. The Drug Enforcement Administration (DEA) is asking for public comments or objections to this application by April 7, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal. The company is not permitted to import these substances for commercial sale, and any registration approval will align with legal requirements.

Benuvia Operations, LLC has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances, which will be used for internal research and developing dosage formulations. The application was submitted on December 4, 2024. The DEA is inviting registered bulk manufacturers and applicants to submit comments or objections electronically by April 14, 2025. Comments should be submitted through the Federal eRulemaking Portal with instructions provided on the regulations.gov website.

Medi-Physics, Inc., which does business as GE Healthcare, has submitted an application to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances. The company intends to import small amounts of Ioflupane, which is an analogue of Cocaine, for research and development purposes, as the required form is unavailable in the U.S. Anyone wishing to comment or request a hearing on this application must do so by February 11, 2021. The DEA's approval will depend on compliance with specific regulatory standards.

The Department of Energy is seeking information to boost the state of accelerator technology in the U.S. They are interested in learning about the current market for particle accelerators, successful partnerships, and ways to strengthen the supply chain. To do this, they are asking for comments on various topics, including technology transfer, workforce development, and collaboration models. Responses will help them develop strategies to enhance U.S. leadership in this technology field.

The Networking and Information Technology Research and Development (NITRD) Program is organizing public meetings throughout 2021. These meetings are facilitated by the Joint Engineering Team (JET) and the Middleware And Grid Interagency Coordination (MAGIC) Team. They provide a platform for people to engage with federal agencies and participate in discussions about research and technological developments. Interested individuals can find meeting details and sign up for updates via the NITRD website or their mailing lists. Public comments are encouraged and may be submitted for consideration.

The Food and Drug Administration (FDA) is reopening the deadline for public comments on a draft guidance for industry titled "Type VII Veterinary Master File for Research and Development and Risk Reviews." Originally, comments were due by March 10, 2025, but the FDA has extended the period by 60 days, allowing comments to be submitted until June 9, 2025. This extension responds to a request for more time to provide thorough feedback before the FDA finalizes the guidance. Comments can be submitted electronically via regulations.gov or as paper submissions to the Dockets Management Staff in Rockville, MD.

Leading Pharma LLC has applied to register as an importer of controlled substances. This application is for research and development purposes, aiming toward creating a new pharmaceutical product that is pending approval by the Food and Drug Administration (FDA). Interested parties can submit comments or request a hearing regarding this application, with a deadline of January 17, 2025. The Drug Enforcement Administration (DEA) will approve the application only if it meets specific legal criteria.

Irvine Labs Inc. has applied to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of certain controlled substances. The application aims to facilitate research and development, as well as distribution to their research customers. The public can submit comments or objections about the application until February 28, 2025, via the Federal eRulemaking Portal. This notice was officially filed and noted by the DEA on December 27, 2024.

Patheon API Inc. has applied to the Drug Enforcement Administration to register as a bulk manufacturer of several controlled substances. The registration would allow the company to import these substances as reference standards for research and development in its API Manufacturing operations. Interested parties, including current registered bulk manufacturers, can submit comments or objections electronically by April 21, 2025, and may also request a hearing on the application by the same date. Comments submitted will be tracked, and successful submissions will receive a Comment Tracking Number.

Patheon API Services, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. They intend to use these substances as reference standards in research and development for API Manufacturing, and not for any commercial sales. People affected by this application can submit comments or request a hearing by April 28, 2025. All comments must be submitted electronically through the Federal eRulemaking Portal.